Funding for this research was provided by:
National French Program of Hospital Clinical Research (2012)
Text and Data Mining valid from 2018-11-14
Received: 28 August 2017
Accepted: 16 October 2018
First Online: 14 November 2018
Ethics approval and consent to participate
: Written informed consent is obtained from subject and caregiver prior to the initiation of the study. The study is carried out in accordance with the French and European Guidelines for Good Clinical Practice, the latest version of the Declaration of Helsinki (Edinburg 2000, Washington 2002, Tokyo 2005) and ICH (International Conference on Harmonisation) Recommendations and Guidelines for Good Clinical Practice.In accordance with law n° 2004.806 and the ethical body governing biomedical research, the approval of the French ‘Comité de Protection des Personnes’ (CPP) has been submitted to ‘CPP Sud Est III’. CLEM study has been registered in the clinical trials (Current Controlled Trials NCT02052947).
: Not applicable
: The authors declare that Avid Radiopharmaceuticals, a Wholly Owned Subsidiary of Eli Lilly & Company has contributed to the funding of 50 doses of Florbetapir for the PET examination.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.